Scientists Launch Project to Bypass Side Effects of Weight Loss Drugs

0 comment

Staff at TrialSite | Quality Journalism

Mar. 16, 2025, 7:00 p.m.

A new three-year project is underway at The University of Aberdeen’s Rowett Institute and University College London to research mechanisms to bypass the side effects that come with using obesity drugs.

Glucagon-like peptide-1 receptor (GLP1)-based medicines such as Ozempic (semaglutide) act in the brain to reduce food intake and have quickly become one of the most effective pharmaceutical tools to tackle obesity.

Quality journalism costs money to produce.

Free access provides up to 10 articles

Subscription options start at $5 per month
which is less than a Starbucks coffee!

Peter Gabriel, MD

"Publishing on TrialSite helped me secure a $20m research grant for my work."

Jona Savinda

"TrialSiteNews is my daily read for what is happening in the industry."